Hospital for Special Surgery, New York, NY, USA.
Curr Opin Pediatr. 2010 Feb;22(1):61-6. doi: 10.1097/MOP.0b013e328334581f.
Osteogenic sarcoma, also known as osteosarcoma, is a primary malignancy of the bone in which spindle cells produce osteoid. Although rare in the general population, these tumors are the most common primary malignancies of bone and the fifth most common primary malignancy of adolescence. This paper aims to provide a general overview on the presentation, radiographic evaluation, and treatment of osteosarcoma as it presents in the pediatric patient population. Particular focus is placed on the importance of a comprehensive team of physicians, including the pediatric oncologist and orthopedic surgeon, to ensure prompt diagnosis and treatment.
Survival for osteosarcoma tumor has changed significantly due to advanced chemotherapeutic regimens; current data place 5-year survival rates at 60% or greater. In addition, limb-sparing surgery has largely supplanted amputation, though the effect of this change on functional outcomes is controversial. Recent studies have shown greatly improved long-term survival data using current therapeutic regimens at tertiary referral centers.
Advancement in chemotherapeutic regimens has allowed improved survival and limb-sparing surgery in the treatment of osteosarcoma.
成骨肉瘤，又称骨肉瘤，是一种以梭形细胞产生骨样组织为特征的骨原发性恶性肿瘤。尽管在普通人群中较为罕见，但这类肿瘤是最常见的骨原发性恶性肿瘤，也是青少年中第五大常见的原发性恶性肿瘤。本文旨在概述成骨肉瘤在儿科患者中的表现、影像学评估和治疗。特别强调了包括儿科肿瘤学家和骨科医生在内的综合医师团队的重要性，以确保及时诊断和治疗。
由于先进的化疗方案，骨肉瘤患者的生存率发生了显著变化；目前的数据显示，5 年生存率在 60%或以上。此外，保肢手术已在很大程度上取代了截肢，尽管这种变化对功能结果的影响存在争议。最近的研究表明，在三级转诊中心使用目前的治疗方案，可大大提高长期生存数据。
化疗方案的进步使骨肉瘤的治疗得以提高生存率和保肢手术。
